CN108671094A - It is a kind of to be used to treat pharmaceutical composition of gout and preparation method thereof - Google Patents
It is a kind of to be used to treat pharmaceutical composition of gout and preparation method thereof Download PDFInfo
- Publication number
- CN108671094A CN108671094A CN201810746258.4A CN201810746258A CN108671094A CN 108671094 A CN108671094 A CN 108671094A CN 201810746258 A CN201810746258 A CN 201810746258A CN 108671094 A CN108671094 A CN 108671094A
- Authority
- CN
- China
- Prior art keywords
- parts
- pharmaceutical composition
- radix
- gout
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 201000005569 Gout Diseases 0.000 title claims abstract description 49
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 40
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 241000255789 Bombyx mori Species 0.000 claims abstract description 25
- 241000282817 Bovidae Species 0.000 claims abstract description 25
- 241000218176 Corydalis Species 0.000 claims abstract description 25
- 244000227573 Desmodium styracifolium Species 0.000 claims abstract description 23
- 241001233914 Chelidonium majus Species 0.000 claims abstract description 22
- 239000000284 extract Substances 0.000 claims description 39
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 37
- 241000233948 Typha Species 0.000 claims description 24
- 235000019441 ethanol Nutrition 0.000 claims description 23
- 239000000843 powder Substances 0.000 claims description 23
- 239000000706 filtrate Substances 0.000 claims description 14
- 239000002775 capsule Substances 0.000 claims description 9
- 238000010992 reflux Methods 0.000 claims description 9
- 238000001914 filtration Methods 0.000 claims description 8
- 239000000463 material Substances 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 8
- 238000004064 recycling Methods 0.000 claims description 7
- 239000000853 adhesive Substances 0.000 claims description 5
- 230000001070 adhesive effect Effects 0.000 claims description 5
- 239000003085 diluting agent Substances 0.000 claims description 5
- 239000007884 disintegrant Substances 0.000 claims description 5
- -1 electuary Substances 0.000 claims description 5
- 239000000314 lubricant Substances 0.000 claims description 5
- 239000003826 tablet Substances 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 4
- 229940126701 oral medication Drugs 0.000 claims description 4
- 239000001828 Gelatine Substances 0.000 claims description 3
- 229920000159 gelatin Polymers 0.000 claims description 3
- 235000019322 gelatine Nutrition 0.000 claims description 3
- 239000011248 coating agent Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 abstract description 18
- 201000010099 disease Diseases 0.000 abstract description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 16
- 210000003734 kidney Anatomy 0.000 abstract description 10
- 230000000202 analgesic effect Effects 0.000 abstract description 5
- 238000000034 method Methods 0.000 abstract description 5
- 230000008506 pathogenesis Effects 0.000 abstract description 5
- 230000001737 promoting effect Effects 0.000 abstract description 5
- 230000017531 blood circulation Effects 0.000 abstract description 4
- 240000001398 Typha domingensis Species 0.000 abstract 1
- 239000008280 blood Substances 0.000 description 26
- 210000004369 blood Anatomy 0.000 description 24
- 230000000694 effects Effects 0.000 description 19
- 239000003814 drug Substances 0.000 description 18
- 241000699666 Mus <mouse, genus> Species 0.000 description 16
- 208000002193 Pain Diseases 0.000 description 14
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 13
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 11
- 229940116269 uric acid Drugs 0.000 description 11
- 229940079593 drug Drugs 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 10
- 239000000243 solution Substances 0.000 description 9
- 239000007789 gas Substances 0.000 description 8
- 231100000862 numbness Toxicity 0.000 description 8
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 7
- 239000000796 flavoring agent Substances 0.000 description 7
- 235000019634 flavors Nutrition 0.000 description 7
- 239000013641 positive control Substances 0.000 description 7
- RYYCJUAHISIHTL-UHFFFAOYSA-N 5-azaorotic acid Chemical compound OC(=O)C1=NC(=O)NC(=O)N1 RYYCJUAHISIHTL-UHFFFAOYSA-N 0.000 description 6
- 241000202807 Glycyrrhiza Species 0.000 description 6
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 6
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 6
- 201000001431 Hyperuricemia Diseases 0.000 description 6
- 238000003304 gavage Methods 0.000 description 6
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 229940010454 licorice Drugs 0.000 description 6
- 229950000193 oteracil Drugs 0.000 description 6
- 206010007247 Carbuncle Diseases 0.000 description 5
- 230000004087 circulation Effects 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 201000000736 Amenorrhea Diseases 0.000 description 3
- 206010001928 Amenorrhoea Diseases 0.000 description 3
- 208000006820 Arthralgia Diseases 0.000 description 3
- 206010019233 Headaches Diseases 0.000 description 3
- 206010062717 Increased upper airway secretion Diseases 0.000 description 3
- 208000004880 Polyuria Diseases 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 206010042674 Swelling Diseases 0.000 description 3
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 3
- 229960003459 allopurinol Drugs 0.000 description 3
- 231100000540 amenorrhea Toxicity 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000036461 convulsion Effects 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 230000035619 diuresis Effects 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- 229960000905 indomethacin Drugs 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 235000021374 legumes Nutrition 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 208000026435 phlegm Diseases 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 230000008736 traumatic injury Effects 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 241000721047 Danaus plexippus Species 0.000 description 2
- 206010013935 Dysmenorrhoea Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010023126 Jaundice Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 206010042170 Strangury Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229940000406 drug candidate Drugs 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000003777 experimental drug Substances 0.000 description 2
- 208000021760 high fever Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 238000005550 wet granulation Methods 0.000 description 2
- XOMKZKJEJBZBJJ-UHFFFAOYSA-N 1,2-dichloro-3-phenylbenzene Chemical group ClC1=CC=CC(C=2C=CC=CC=2)=C1Cl XOMKZKJEJBZBJJ-UHFFFAOYSA-N 0.000 description 1
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010061623 Adverse drug reaction Diseases 0.000 description 1
- 240000007185 Albizia julibrissin Species 0.000 description 1
- 235000011468 Albizia julibrissin Nutrition 0.000 description 1
- 241001254604 Angelica pubescens Species 0.000 description 1
- 241000208327 Apocynaceae Species 0.000 description 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- 235000017491 Bambusa tulda Nutrition 0.000 description 1
- 206010006002 Bone pain Diseases 0.000 description 1
- 206010007027 Calculus urinary Diseases 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 241000125183 Crithmum maritimum Species 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 241000522190 Desmodium Species 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000967672 Gentiana crassicaulis Species 0.000 description 1
- 241000501719 Gentiana straminea Species 0.000 description 1
- 241001071804 Gentianaceae Species 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- UHJOFHKUHLWIMU-UHFFFAOYSA-N N1CCNCC1.[O] Chemical compound N1CCNCC1.[O] UHJOFHKUHLWIMU-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010030302 Oliguria Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 241000218180 Papaveraceae Species 0.000 description 1
- 244000082204 Phyllostachys viridis Species 0.000 description 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 206010044684 Trismus Diseases 0.000 description 1
- 241001518821 Typha orientalis Species 0.000 description 1
- 206010046337 Urate nephropathy Diseases 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 208000026816 acute arthritis Diseases 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 239000011425 bamboo Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 230000002279 cholagogic effect Effects 0.000 description 1
- 239000000039 congener Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000003821 menstrual periods Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 230000001617 migratory effect Effects 0.000 description 1
- NAFSTSRULRIERK-UHFFFAOYSA-M monosodium urate Chemical compound [Na+].N1C([O-])=NC(=O)C2=C1NC(=O)N2 NAFSTSRULRIERK-UHFFFAOYSA-M 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000010382 simiaowan Substances 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000003424 uricosuric effect Effects 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 208000008281 urolithiasis Diseases 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/27—Asclepiadaceae (Milkweed family), e.g. hoya
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/51—Gentianaceae (Gentian family)
- A61K36/515—Gentiana
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/66—Papaveraceae (Poppy family), e.g. bloodroot
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Rheumatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Insects & Arthropods (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to a kind of pharmaceutical composition and preparation method thereof for treating gout, described pharmaceutical composition is made of Radix Salviae Miltiorrhizae, radix cyathulae, Radix Angelicae Pubescentis, bark of ash, corydalis tuber, stiff silkworm, cortex albiziae, Desmodium styracifolium, cattail pollen, antelope's horn, unpleasant swallowwort herb and Radix Glycyrrhizae.Pharmaceutical composition of the present invention is directed to the etiology and pathogenesis of gout, using promoting blood circulation, based on wind-dispelling, takes into account the nourishing liver and kidney method with analgesic, can treating both manifestation and root cause of disease treatment gout.
Description
Technical field
The invention belongs to the field of Chinese medicines, and in particular to a kind of for treating pharmaceutical composition of gout and preparation method thereof.
Background technology
Gout (Gout) refers to disease caused by the purine metabolic disturbance caused by a variety of causes and/or underexcretion
Disease can lead to the recurrent exerbation of acute arthritis, uric acid with the characteristics of forming Monosodium urate crystallization in joint part and its hetero-organization
Sodium crystallization can further form bulk, form tophus, cause chornic arthritis, joint deformity, or even can lead to function of joint
Forfeiture, uric-acid calculus can also be generated in kidney, and gouty nephropathy is caused to become.Gout be apt to occur in 40-50 Sui male and absolutely
Women after menstrual period, but age of onset is gradually to the development that becomes younger.According to epidemiological study, China suffers from high lithemia at present
The patient of mass formed by blood stasis alreadys exceed 100,000,000 people, and is diagnosed as the patient of gout nearly 20,000,000 people, and also left with annual 10%
Right speed increase, patient suffering can't bear when gout is broken out, and become one of the disease for seriously affecting people's live and work.
Doctor trained in Western medicine using anti-inflammatory analgetic class drug, inhibits uric acid shape for the treatment of gout generally from its symptom at present
Class drug etc. is drained at class drug or uricosuric, is only capable of alleviating the clinical symptoms of gout to a certain extent, takes stopgap measures and cannot control
This, and needs Long-term taking medicine to alleviate symptom, is quickly recurred after drug withdrawal, and not only therapeutic effect is limited, can also give patient with
Come serious drug side-effect, such as Nausea and vomiting, indigestion, headache, dizziness.
Chinese medicine thinks that gout belongs to the scope of traditional Chinese medicine " rheumatism ",《Plain Questions numbness opinion》A piece points out " so-called numbness person, respectively with it
When, the wet gas of being affected wind-cold repeatedly ", the transient cause that rheumatism occurs has that " three gas of wind, cold, wet is miscellaneous extremely, combined into numbness.Its general mood wins
Person is migratory arthralgia, and BI-syndrome caused mainly by pathogenic cold being called painful BI, moisture victor is numbness." gout exists by ZHU Dan-xi first as name of disease《Further Discourses on the Properties of Things》
Middle proposition, " gout and pain has a normal place, sore spot is red swollen scorching hot, or high fever from head to foot ", and propose " with hot agent, cold-dampness of scattering,
Develop space between skin and muscles, blood must be capable " gout treatment principle.Later age Chinese medicine doctor to the etiology and pathogenesis of gout carried out supplement and it is rich
It is rich, it is believed that the etiology and pathogenesis of gout includes：Insufficiency of natural endowment, caused by liver and kidney deficiency, Ying Wei become estranged, deficiency of vital energy and blood, phlegm wet numbness hinder, in gout
Sick initial stage positive unsaturated vapor, causes to invade in exopathogen, stops up resistance channels and collaterals, and QI-blood circulation is unsmooth, and wind-cold-dampness arthralgia resistance increases.The liver belonging to wood, kidney category
Water, regulation between water and fire, the two share success, and a damage is all damaged.If caused by liver and kidney deficiency, also virtual loss, muscles and bones lose foster, the laboured breathing of liver kidney to essence and blood
It is weak, then susceptible wind-cold damp pathogen and fall ill.Defend gas and be primarily referred to as function basis in traditional Chinese medicine scope --- outside defending, defend, and ying blood
It is mainly then material base, the two can influence each other again, mutually restrain；From sick position, gas is defended in table, and ying blood is in inner, gas
For the general of blood, blood being the material foundation of QI, blood contains that then gas is prosperous, and the prosperous then blood of gas is contained, gas row then blood, and the stagnation of the circulation of vital energy then blood stasis, battalion, which defends, to become estranged then easily
Feel exopathogen, exopathogen invasion easily causes QI-blood circulation unsmooth, and tendon and vessel, which is lost, supports.For the treatment of gout, successively there is gout and dissipate, bitterly
Wind soup, SIMIAO WAN, Simiao San plus-minus plus taste Punching line etc., achieve certain therapeutic effect, but still undesirable.
Present inventor provides one kind on the basis of having studied existing gout etiology and pathogenesis and the therapy rules for the treatment of comprehensively
Effect preferably treats the pharmaceutical composition and preparation method thereof of gout.
Invention content
The object of the present invention is to provide a kind of pharmaceutical compositions for treating gout, it is characterised in that by Radix Salviae Miltiorrhizae, river ox
Knee, Radix Angelicae Pubescentis, bark of ash, corydalis tuber, stiff silkworm, cortex albiziae, Desmodium styracifolium, cattail pollen, antelope's horn, unpleasant swallowwort herb and Radix Glycyrrhizae are made.
Preferably, described pharmaceutical composition is by 10-15 parts of Radix Salviae Miltiorrhizae, 10-15 parts of radix cyathulae, 10-15 parts of Radix Angelicae Pubescentis, bark of ash 5-10
It is part, 5-10 parts of corydalis tuber, 5-10 parts of stiff silkworm, 3-5 parts of cortex albiziae, 3-5 parts of Desmodium styracifolium, 3-5 parts of cattail pollen, 1-2 parts of antelope's horn, old
1-2 parts of 1-2 parts of monarch's palpus and Radix Glycyrrhizae are made.
Preferably, described pharmaceutical composition is by 12-14 parts of Radix Salviae Miltiorrhizae, 12-14 parts of radix cyathulae, 12-14 parts of Radix Angelicae Pubescentis, bark of ash 6-8
Part, 6-8 parts of corydalis tuber, 6-8 parts of stiff silkworm, 2-4 parts of cortex albiziae, 2-4 parts of Desmodium styracifolium, 2-4 parts of cattail pollen, 1-2 parts of antelope's horn, old monarch
1-2 parts of 1-2 parts of palpus and Radix Glycyrrhizae are made.
Preferably, described pharmaceutical composition is by 13 parts of Radix Salviae Miltiorrhizae, 13 parts of radix cyathulae, 13 parts of Radix Angelicae Pubescentis, 13 parts of bark of ash, corydalis tuber 7
2 parts of part, 7 parts of stiff silkworm, 3 parts of cortex albiziae, 3 parts of Desmodium styracifolium, 3 parts of cattail pollen, 1 part of antelope's horn, 1 part of unpleasant swallowwort herb and Radix Glycyrrhizae are made.
Pharmaceutical composition of the present invention is prepared into combination of oral medication after adding pharmaceutically acceptable auxiliary material, described oral
The dosage form of pharmaceutical composition is selected from：Decoction, granule, electuary, pill, powder, tablet, capsule etc., it is preferred that described oral
The dosage form of pharmaceutical composition is selected from decoction, tablet or capsule.
Preferably, the pharmaceutically acceptable auxiliary material is selected from：Diluent, adhesive, disintegrant, lubricant help stream
Agent, corrigent, coating agent, gelatine capsule shell and combinations thereof.
It is furthermore preferred that the diluent is selected from starch, dextrin, microcrystalline cellulose etc.；Described adhesive is selected from：Starch slurry,
Hydroxypropyl methyl cellulose, sodium carboxymethylcellulose, povidone etc.；The disintegrant is selected from sodium carboxymethyl starch, the poly- dimension of crosslinking
Ketone, croscarmellose sodium etc.；The lubricant or glidant are selected from：Magnesium stearate, talcum powder, superfine silica gel powder etc..
It is also another object of the present invention to provide a kind of pharmaceutical composition preparation methods for treating gout comprising with
Lower step：
(1) it stocks up：Each bulk pharmaceutical chemicals are weighed according to formula；
(2) it crushes：It is uniformly mixed after stiff silkworm, antelope's horn, cattail pollen are smashed it through 30-60 mesh sieve respectively, it is spare to obtain powder；
(3) it extracts：By Radix Salviae Miltiorrhizae, radix cyathulae, Radix Angelicae Pubescentis, bark of ash, corydalis tuber, cortex albiziae, Desmodium styracifolium, unpleasant swallowwort herb and licorice powder
It is broken, it is uniformly mixed after crossing 10-20 mesh sieve, 2-4 times of addition is measured 50-80% alcohol refluxs and extracted 1-3 times, each 1-2h, extracting solution
Filtration, filtrate merge, the medicinal extract that relative density is 1.02-1.05 when optional reduced pressure is 25 DEG C after recycling ethyl alcohol；
(4) preparation：Filtrate or medicinal extract after powder obtained by step (2) is recycled ethyl alcohol with step (3) gained mix, and add
After pharmaceutically acceptable auxiliary material, the pharmaceutical composition of present invention treatment gout is made.
Preferably, 40 mesh sieve is crossed in the step (2)；The step (3) is uniformly mixed after crossing 20 mesh sieve, adds 3 times of amounts
70% alcohol reflux extracts 2 times, each 1.5h, and extracting solution filtration, filtrate merges, and optional reduced pressure is 25 after recycling ethyl alcohol
DEG C when relative density be 1.02-1.05 medicinal extract.
The effect of each raw material, is as follows in pharmaceutical composition of the present invention：
Radix Salviae Miltiorrhizae, bitter, cold nature, converge to heart and liver channels are the dry root and rhizome of labiate Radix Salviae Miltiorrhizae, there is promoting blood circulation to dispel
The effect of stasis of blood, inducing meastruation to relieve menalgia, relieving restlessness that clears away heart-fire, cool blood to disappear carbuncle, it is usually used in chest impediment and cardialgia, hot numbness pain, dysphoria and insomnia, menstruation not
It adjusts, the treatment of dysmenorrhoea Amenorrhea, sore, carbuncle and painful swelling.
Radix cyathulae, sweet in flavor, slight bitter is mild-natured, returns liver and kidney channel, is the dry root of amaranthaceous plant radix cyathulae, has logical by the stasis of blood
The effect of through, easing joint movement, inducing diuresis for treating strangurtia, is usually used in Amenorrhea abdominal mass, traumatic injury, foot and withers the controlling of the diseases such as spasm, hematuria, blood strangury
It treats.
Radix Angelicae Pubescentis, acrid flavour, hardship, slightly warm in nature return kidney, bladder warp, are the dry root of samphire Angelica pubescens, have and dispel
The effect of wind dehumidifying, numbness relieving and pain relieving, it is usually used in the treatment of wind-cold-dampness arthralgia, lumbocrural pain etc..
Bark of ash, acrid flavour, hardship are mild-natured, return stomach, liver, gallbladder channel, be gentianaceae plant bark of ash, gentiana straminea maxim, gentiana crassicaulis Duthie it is dry
Dry, have effects that wind-damp dispelling, stopping numbness pain, reducing the asthenic fever, is usually used in the treatment of the diseases such as muscle arteries and veins contraction, skeletal pain.
Corydalis tuber, acrid flavour, hardship are warm-natured, Return liver, the spleen channel, be papaveraceae plant corydalis dry tuber, have promoting blood circulation,
The effect of promoting the circulation of qi, analgesic, it is usually used in the diseases such as chest side of body epigastric pain, chest impediment and cardialgia, closed dysmenorrhea, postpartum stasis, treating swelling and pain by traumatic injury
Treatment.
Stiff silkworm, taste is salty, pungent, mild-natured, Return liver, lung, stomach, the lethal larva drying for Bombycidae silkworm infection muscardine
Body has effects that Inflammation Zhijing, wind-expelling pain-stopping, reducing phlegm and resolving masses, is usually used in twitch, lockjaw, headache due to pathogenic wind-heat, hot eyes pharynx
Bitterly, the treatment of the diseases such as rubella itch.
Cortex albiziae, sweet in flavor, mild-natured, converge to heart and liver channels are the dry bark of legume silk tree, with the strongly fragrant and blood of solution, rather
The effect of heart, subduing inflammation, is usually used in the treatment of the diseases such as confused and worried, melancholy, insomnia, carbuncle swells, traumatic injury.
Desmodium styracifolium, sweet in flavor, light, cool in nature, Return liver, kidney, bladder warp are the drying overground part of legume Desmodium styracifolium
Point, have effects that removing dampness through diuresis and removing jaundice, inducing diuresis for treating strangurtia, is usually used in the diseases such as jaundice, heat gonorrhea, urolithiasis, difficulty and pain in micturition, oedema oliguria
Treatment.
Cattail pollen, sweet in flavor, mild-natured, Return liver, pericardium channel are Typhaceae plant raupo cattail, typha orientalis or congener
Dry pollen has effects that hemostasis, treating stranguria, stagnation resolvation, is usually used in haematemesis, spitting of blood, uterine bleeding, wound, Amenorrhea, chest and abdomen shouting pain, falls
Play the treatment of the diseases such as swelling and pain, blood strangury and dry pain.
Antelope's horn, taste is salty, cold in nature, Return liver, the heart channel of Hang-Shaoyin, is the angle of male bovid sahilite, with suppressing hyperactive liver for calming endogenous wind, clearly
Liver improving eyesight, dissipate blood removing toxic substances the effect of, be usually used in liver wind agitation, twitch, high fever convulsion faint, epilepsy, dizziness of having a headache, carbuncle sore tumefacting virus
The treatment of equal diseases.
Unpleasant swallowwort herb, bitter, micro-pungent are mild-natured, distributed in lung channel, for root or aerial part that Asclepiadaceae plant bamboo spirit disappears, have clear
The effect of hot cool blood, cholagogic, removing toxic substances, is usually used in fever due to yin deficiency, consumptive disease is coughed long, spit blood, the distending pain in hypochondrium, vomiting of exerting one's utmost effort, postpartum are empty
The treatment of the diseases such as tired, nameless gall.
Radix Glycyrrhizae has and invigorates the spleen and benefits qi, clearly for glycyrrhizic legume, the dry root and rhizome of swollen fruit Radix or glycyrrhiza glabra
The effect of thermal detoxification, expelling phlegm and arresting coughing, relieving spasm to stop pain, coordinating the drug actions of a prescription, is usually used in weakness of the spleen and the stomach, lassitude hypodynamia, palpitation, cough
The treatment of abundant expectoration, carbuncle swells sore pain, and alleviate the toxicity, strong of drug.
Advantageous effect of the present invention
1. pharmaceutical composition of the present invention is directed to the etiology and pathogenesis of gout, using promoting blood circulation, based on wind-dispelling, take into account it is nourishing liver and kidney with
The method of analgesic, can treating both manifestation and root cause of disease treatment gout.
2. the prescription of pharmaceutical composition of the present invention is simple, each bulk pharmaceutical chemicals compatibility is reasonable, and the therapeutic effect of gout is better than existing
Gout treatment drug.
3. pharmaceutical composition safety of the present invention, has no toxic side effect.
4. pharmaceutical composition preparation method of the present invention is simple, it is suitble to industrialized production.
Specific implementation mode
The present invention is described below in more detail to contribute to the understanding of the present invention.
Embodiment 1:A kind of decoction for treating gout
It is 13 parts of Radix Salviae Miltiorrhizae, 13 parts of radix cyathulae, 13 parts of Radix Angelicae Pubescentis, 13 parts of bark of ash, 7 parts of corydalis tuber, 7 parts of stiff silkworm, 3 parts of cortex albiziae, wide
2 parts of 3 parts of desmodium, 3 parts of cattail pollen, 1 part of antelope's horn, 1 part of unpleasant swallowwort herb and Radix Glycyrrhizae.
It prepares in accordance with the following methods：
(1) it stocks up：Each bulk pharmaceutical chemicals are weighed according to formula；
(2) it crushes：It is uniformly mixed after stiff silkworm, antelope's horn, cattail pollen are smashed it through 40 mesh sieve respectively, it is spare to obtain powder；
(3) it extracts：By Radix Salviae Miltiorrhizae, radix cyathulae, Radix Angelicae Pubescentis, bark of ash, corydalis tuber, cortex albiziae, Desmodium styracifolium, unpleasant swallowwort herb and licorice powder
It is broken, it is uniformly mixed after crossing 20 mesh sieve, adds 3 times of 70% alcohol refluxs of amount and extract 2 times, each 1.5h, extracting solution filtration, filtrate is closed
And recycle ethyl alcohol；
(4) preparation：After powder obtained by step (2) is mixed with the filtrate after recycling ethyl alcohol obtained by step (3), this hair is made
Mingzhi treats the pharmaceutical composition of gout.
Embodiment 2：A kind of tablet for treating gout
10 parts of Radix Salviae Miltiorrhizae, 10 parts of radix cyathulae, 10 parts of Radix Angelicae Pubescentis, 5 parts of bark of ash, 5 parts of corydalis tuber, 5 parts of stiff silkworm, 3 parts of cortex albiziae, wide gold
1 part of 3 parts of money grass, 3 parts of cattail pollen, 1 part of antelope's horn, 1 part of unpleasant swallowwort herb and Radix Glycyrrhizae.
(1) it stocks up：Each bulk pharmaceutical chemicals are weighed according to formula；
(2) it crushes：It is uniformly mixed after stiff silkworm, antelope's horn, cattail pollen are smashed it through 60 mesh sieve respectively, it is spare to obtain powder；
(3) it extracts：By Radix Salviae Miltiorrhizae, radix cyathulae, Radix Angelicae Pubescentis, bark of ash, corydalis tuber, cortex albiziae, Desmodium styracifolium, unpleasant swallowwort herb and licorice powder
It is broken, it is uniformly mixed after crossing 20 mesh sieve, adds 2 times of 80% alcohol refluxs of amount and extract 2 times, each 1h, extracting solution filtration, filtrate is closed
And the medicinal extract that relative density is 1.02-1.05 when optional reduced pressure is 25 DEG C after recycling ethyl alcohol；
(4) preparation：Filtrate or medicinal extract after powder obtained by step (2) is recycled ethyl alcohol with step (3) gained mix, and add
The pharmaceutical composition of present invention treatment gout is made in tabletting after wet granulation after diluent, adhesive, disintegrant, lubricant.
Embodiment 3, a kind of capsule for treating gout.
15 parts of Radix Salviae Miltiorrhizae, 15 parts of radix cyathulae, 15 parts of Radix Angelicae Pubescentis, 10 parts of bark of ash, 10 parts of corydalis tuber, 10 parts of stiff silkworm, 5 parts of cortex albiziae,
2 parts of 5 parts of Desmodium styracifolium, 5 parts of cattail pollen, 2 parts of antelope's horn, 2 parts of unpleasant swallowwort herb and Radix Glycyrrhizae.
(1) it stocks up：Each bulk pharmaceutical chemicals are weighed according to formula；
(2) it crushes：It is uniformly mixed after stiff silkworm, antelope's horn, cattail pollen are smashed it through 30 mesh sieve respectively, it is spare to obtain powder；
(3) it extracts：By Radix Salviae Miltiorrhizae, radix cyathulae, Radix Angelicae Pubescentis, bark of ash, corydalis tuber, cortex albiziae, Desmodium styracifolium, unpleasant swallowwort herb and licorice powder
It is broken, it is uniformly mixed after crossing 10 mesh sieve, adds 4 times of 50% alcohol refluxs of amount and extract 2 times, each 2h, extracting solution filtration, filtrate is closed
And the medicinal extract that relative density is 1.02-1.05 when optional reduced pressure is 25 DEG C after recycling ethyl alcohol；
(4) preparation：Filtrate or medicinal extract after powder obtained by step (2) is recycled ethyl alcohol with step (3) gained mix, and add
It is filled in gelatine capsule shell after wet granulation after diluent, adhesive, disintegrant, lubricant, present invention treatment gout is made
Capsule.
Effect example 1：Pharmaceutical composition of the present invention causes Oteracil Potassium the influence of mouse hyperuricemia
1.1 experimental drug
Chinese medical extract 1 of the present invention：13 parts of Radix Salviae Miltiorrhizae, 13 parts of radix cyathulae, 13 parts of Radix Angelicae Pubescentis, 13 parts of bark of ash, 7 parts of corydalis tuber, deadlock
2 parts of 7 parts of silkworm, 3 parts of cortex albiziae, 3 parts of Desmodium styracifolium, 3 parts of cattail pollen, 1 part of antelope's horn, 1 part of unpleasant swallowwort herb and Radix Glycyrrhizae；
Chinese medical extract 2 of the present invention：15 parts of Radix Salviae Miltiorrhizae, 15 parts of radix cyathulae, 15 parts of Radix Angelicae Pubescentis, 10 parts of bark of ash, 10 parts of corydalis tuber, deadlock
2 parts of 10 parts of silkworm, 5 parts of cortex albiziae, 5 parts of Desmodium styracifolium, 5 parts of cattail pollen, 2 parts of antelope's horn, 2 parts of unpleasant swallowwort herb and Radix Glycyrrhizae；
Chinese medical extract 3 of the present invention：10 parts of Radix Salviae Miltiorrhizae, 10 parts of radix cyathulae, 10 parts of Radix Angelicae Pubescentis, 5 parts of bark of ash, 5 parts of corydalis tuber, stiff silkworm
1 part of 5 parts, 3 parts of cortex albiziae, 3 parts of Desmodium styracifolium, 3 parts of cattail pollen, 1 part of antelope's horn, 1 part of unpleasant swallowwort herb and Radix Glycyrrhizae；
Positive control drug：Allopurinol.
Chinese medical extract 1-3 wherein of the present invention is prepared in accordance with the following methods：
(1) it stocks up：Each bulk pharmaceutical chemicals are weighed according to formula；
(2) it crushes：It is uniformly mixed after stiff silkworm, antelope's horn, cattail pollen are smashed it through 40 mesh sieve respectively, it is spare to obtain powder；
(3) it extracts：By Radix Salviae Miltiorrhizae, radix cyathulae, Radix Angelicae Pubescentis, bark of ash, corydalis tuber, cortex albiziae, Desmodium styracifolium, unpleasant swallowwort herb and licorice powder
It is broken, it is uniformly mixed after crossing 20 mesh sieve, adds 3 times of 70% alcohol refluxs of amount and extract 2 times, each 1.5h, extracting solution filtration, filtrate is closed
And ethyl alcohol is recycled, the medicinal extract that relative density when being 25 DEG C is 1.02-1.05 is concentrated under reduced pressure, powder is mixed obtained by addition step (2)
It closes, the pharmaceutical composition of present invention treatment gout is made, Chinese medical extract of the present invention is made.
The foundation of 1.2 experimental models
It is right to be randomly divided into blank group, model group, 1-3 groups of the present invention and the positive for male mouse of kunming 60, weight 18-22g
According to group, every group 10, after adaptability raises 1d, gastric infusion, wherein blank group and model group gavage physiological saline, 1- of the present invention
3 groups and positive controls gavage relative medicine, gavage volume are 0.5ml, wherein 1-3 groups dosage 10g crude drugs/Kg of the present invention
Weight, positive controls dosage 0.05g/Kg weight.It is administered once daily, successive administration 7 days, after last dose 1h, removes blank
Group is outer, other each group mouse be injected intraperitoneallys Oteracil Potassium 0.3g/Kg weight, after 2h, venous blood collection after mouse orbit, and measurement blood
Clear uric acid content calculates serum uric acid inhibiting rate, and concrete outcome is shown in Table 1, wherein
Serum uric acid inhibiting rate=(model group serum uric acid-experimental group serum uric acid)/model group serum urine
Acid content × 100%.
1.3 experimental result
The multifactor analysis of variance module of applied statistics software SPSS carries out data analysis, P<0.05 expression difference has statistics
Learn meaning.
1 pharmaceutical composition of table causes Oteracil Potassium the influence of mouse hyperuricemia
Compared with blank group：△△P<0.01；Compared with model group：*P<0.05,**P<0.01.
1 experimental result of table shows that model group mice serum uric acid content obviously increases after Oteracil Potassium is injected intraperitoneally, and shows
There is certain journey in mice serum uric acid level after modeling success, gastric infusion Chinese medical extract 1-3 of the present invention and allopurinol
The reduction of degree, wherein allopurinol are 17.92% to the serum uric acid inhibiting rate of hyperuricemia mouse caused by Oteracil Potassium, and
Chinese medical extract 1 of the present invention inhibits the most apparent to the serum uric acid of hyperuricemia mouse caused by Oteracil Potassium, to oxygen piperazine
The serum uric acid inhibiting rate of hyperuricemia mouse caused by sour potassium reached 26.51%, it was demonstrated that Chinese medical extract tool of the present invention
There is the effect of excellent inhibition hyperuricemia.
Effect example 2：The influence that mouse writhing caused by pharmaceutical composition Dichlorodiphenyl Acetate of the present invention reacts
2.1 experimental drug
Chinese medical extract 1 of the present invention：13 parts of Radix Salviae Miltiorrhizae, 13 parts of radix cyathulae, 13 parts of Radix Angelicae Pubescentis, 13 parts of bark of ash, 7 parts of corydalis tuber, deadlock
2 parts of 7 parts of silkworm, 3 parts of cortex albiziae, 3 parts of Desmodium styracifolium, 3 parts of cattail pollen, 1 part of antelope's horn, 1 part of unpleasant swallowwort herb and Radix Glycyrrhizae, in accordance with the following methods
It prepares：
(1) it stocks up：Each bulk pharmaceutical chemicals are weighed according to formula；
(2) it crushes：It is uniformly mixed after stiff silkworm, antelope's horn, cattail pollen are smashed it through 40 mesh sieve respectively, it is spare to obtain powder；
(3) it extracts：By Radix Salviae Miltiorrhizae, radix cyathulae, Radix Angelicae Pubescentis, bark of ash, corydalis tuber, cortex albiziae, Desmodium styracifolium, unpleasant swallowwort herb and licorice powder
It is broken, it is uniformly mixed after crossing 20 mesh sieve, adds 3 times of 70% alcohol refluxs of amount and extract 2 times, each 1.5h, extracting solution filtration, filtrate is closed
And ethyl alcohol is recycled, the medicinal extract that relative density when being 25 DEG C is 1.02-1.05 is concentrated under reduced pressure, powder is mixed obtained by addition step (2)
It closes, the pharmaceutical composition of present invention treatment gout is made, Chinese medical extract of the present invention is made.
Positive control drug：Indomethacin.
Modeling agent：0.6% acetum.
The foundation of 2.2 experimental models
Male mouse of kunming 30, weight 18-22g, is randomly divided into model group, of the present invention group and positive controls, every group
10, after adaptability raises 1d, gastric infusion, wherein model group gavage physiological saline, of the present invention group and positive controls gavage
Relative medicine, gavage volume are 0.5ml, wherein present invention group dosage 10g crude drugs/Kg weight, positive controls dosage
0.01g/Kg weight.It is administered once daily, successive administration 7 days, after last dose 1h, 0.6% acetic acid is injected intraperitoneally in each group mouse
Solution 0.2mL/ only, records mouse writhing number in 20 minutes, and calculate Chinese medical extract and Indomethacin Dichlorodiphenyl Acetate of the present invention
The inhibiting rate of caused mouse writhing reaction, concrete outcome are shown in Table 2, wherein
Inhibiting rate=(model group writhing number-experimental group writhing number)/model group writhing number of mouse writhing reaction
× 100%.
2.3 experimental result
The multifactor analysis of variance module of applied statistics software SPSS carries out data analysis, P<0.05 expression difference has statistics
Learn meaning.
2 pharmaceutical composition Dichlorodiphenyl Acetate of table causes the influence of mouse writhing reaction
Compared with model group：**P<0.01.
2 experimental result of table shows that mouse is because being injected intraperitoneally vinegar after gastric infusion Chinese medical extract of the present invention and Indomethacin
Writhing response number caused by acid significantly reduces, it was demonstrated that Chinese medical extract of the present invention has excellent analgesic effect.
The foregoing describe the preferred embodiment for the present invention, and however, it is not to limit the invention.Those skilled in the art couple
Embodiment disclosed herein can carry out improvement and the variation without departing from scope and spirit.
Claims (10)
1. a kind of for treating the pharmaceutical composition of gout, which is characterized in that by Radix Salviae Miltiorrhizae, radix cyathulae, Radix Angelicae Pubescentis, bark of ash, corydalis tuber,
Stiff silkworm, cortex albiziae, Desmodium styracifolium, cattail pollen, antelope's horn, unpleasant swallowwort herb and Radix Glycyrrhizae are made.
2. the pharmaceutical composition for the treatment of gout according to claim 1, which is characterized in that by 10-15 parts of Radix Salviae Miltiorrhizae, radix cyathulae
10-15 parts, 10-15 parts of Radix Angelicae Pubescentis, 5-10 parts of bark of ash, 5-10 parts of corydalis tuber, 5-10 parts of stiff silkworm, 3-5 parts of cortex albiziae, Desmodium styracifolium 3-
1-2 parts of 5 parts, 3-5 parts of cattail pollen, 1-2 parts of antelope's horn, 1-2 parts of unpleasant swallowwort herb and Radix Glycyrrhizae are made.
3. the pharmaceutical composition for the treatment of gout according to claim 2, which is characterized in that by 12-14 parts of Radix Salviae Miltiorrhizae, radix cyathulae
12-14 parts, 12-14 parts of Radix Angelicae Pubescentis, 6-8 parts of bark of ash, 6-8 parts of corydalis tuber, 6-8 parts of stiff silkworm, 2-4 parts of cortex albiziae, Desmodium styracifolium 2-4
1-2 parts of part, 2-4 parts of cattail pollen, 1-2 parts of antelope's horn, 1-2 parts of unpleasant swallowwort herb and Radix Glycyrrhizae are made.
4. the pharmaceutical composition for the treatment of gout according to claim 2, which is characterized in that by 13 parts of Radix Salviae Miltiorrhizae, radix cyathulae 13
Part, 13 parts of Radix Angelicae Pubescentis, 13 parts of bark of ash, 7 parts of corydalis tuber, 7 parts of stiff silkworm, 3 parts of cortex albiziae, 3 parts of Desmodium styracifolium, 3 parts of cattail pollen, antelope's horn 1
2 parts of part, 1 part of unpleasant swallowwort herb and Radix Glycyrrhizae are made.
5. treating the pharmaceutical composition of gout according to claim 1-4 any one of them, which is characterized in that the pharmaceutical composition
Object is prepared into combination of oral medication after adding pharmaceutically acceptable auxiliary material.
6. the pharmaceutical composition for the treatment of gout according to claim 5, which is characterized in that described pharmaceutically acceptable auxiliary
Material is selected from：Diluent, adhesive, disintegrant, lubricant or glidant, corrigent, coating agent, gelatine capsule shell and combinations thereof.
7. the pharmaceutical composition for the treatment of gout according to claim 5, which is characterized in that the combination of oral medication choosing
From：Decoction, granule, electuary, pill, powder, tablet or capsule.
8. the pharmaceutical composition for the treatment of gout according to claim 6, which is characterized in that the combination of oral medication choosing
From decoction, tablet or capsule.
9. claim 1-8 any one of them treat gout pharmaceutical composition preparation method, which is characterized in that including with
Lower step：
(1) it stocks up：Each bulk pharmaceutical chemicals are weighed according to formula；
(2) it crushes：It is uniformly mixed after stiff silkworm, antelope's horn, cattail pollen are smashed it through 30-60 mesh sieve respectively, it is spare to obtain powder；
(3) it extracts：Radix Salviae Miltiorrhizae, radix cyathulae, Radix Angelicae Pubescentis, bark of ash, corydalis tuber, cortex albiziae, Desmodium styracifolium, unpleasant swallowwort herb and Radix Glycyrrhizae are crushed,
It is uniformly mixed after crossing 10-20 mesh sieve, 2-4 times of addition is measured 50-80% alcohol refluxs and extracted 1-3 times, each 1-2h, extracting solution filter
It crosses, filtrate merges, the medicinal extract that relative density is 1.02-1.05 when optional reduced pressure is 25 DEG C after recycling ethyl alcohol；
(4) preparation：Filtrate or medicinal extract after powder obtained by step (2) is recycled ethyl alcohol with step (3) gained mix, and add pharmacy
After upper acceptable auxiliary material, the pharmaceutical composition for the treatment of gout is made.
10. preparation method according to claim 9, it is characterised in that：40 mesh sieve is crossed in the step (2)；The step
(3) it is uniformly mixed after crossing 20 mesh sieve, adds 3 times of 70% alcohol refluxs of amount and extract 2 times, each 1.5h, extracting solution filtration, filtrate is closed
And the medicinal extract that relative density is 1.02-1.05 when optional reduced pressure is 25 DEG C after recycling ethyl alcohol.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810746258.4A CN108671094B (en) | 2018-07-09 | 2018-07-09 | A pharmaceutical composition for treating gout and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810746258.4A CN108671094B (en) | 2018-07-09 | 2018-07-09 | A pharmaceutical composition for treating gout and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108671094A true CN108671094A (en) | 2018-10-19 |
| CN108671094B CN108671094B (en) | 2021-10-01 |
Family
ID=63813539
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810746258.4A Active CN108671094B (en) | 2018-07-09 | 2018-07-09 | A pharmaceutical composition for treating gout and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108671094B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101869670A (en) * | 2010-06-08 | 2010-10-27 | 江苏南星药业有限责任公司 | Anti-gout composition, preparation method and application thereof in preparation of anti-gout drugs |
| CN103893363A (en) * | 2013-10-28 | 2014-07-02 | 东南大学 | Traditional Chinese medicine composition for treating chronic gout and fabrication method thereof |
| CN103933224A (en) * | 2014-04-30 | 2014-07-23 | 周晓明 | Traditional Chinese medicine composition for treating gout |
-
2018
- 2018-07-09 CN CN201810746258.4A patent/CN108671094B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101869670A (en) * | 2010-06-08 | 2010-10-27 | 江苏南星药业有限责任公司 | Anti-gout composition, preparation method and application thereof in preparation of anti-gout drugs |
| CN103893363A (en) * | 2013-10-28 | 2014-07-02 | 东南大学 | Traditional Chinese medicine composition for treating chronic gout and fabrication method thereof |
| CN103933224A (en) * | 2014-04-30 | 2014-07-23 | 周晓明 | Traditional Chinese medicine composition for treating gout |
Non-Patent Citations (1)
| Title |
|---|
| 孙晶，等: ""中医药治疗痛风病的研究进展"", 《中医药信息》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN108671094B (en) | 2021-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100415280C (en) | A Chinese traditional medicinal preparation for treatment of urticaria | |
| CN102284022A (en) | Cough medicament and preparation method thereof | |
| CN108210791A (en) | For treating the Chinese medicine of gout and preparation method | |
| CN104069391A (en) | Traditional Chinese medicine composition for treating gout and hyperuricemia and preparation method thereof | |
| CN104147536A (en) | Medicine composition for treating haemorrhoids and preparation method thereof | |
| CN104027684A (en) | Traditional Chinese medicinal composition for treating gout and preparation method thereof | |
| CN100415281C (en) | A Chinese traditional medicinal preparation for treatment of urticaria | |
| CN114747766A (en) | Health-care food composition capable of reducing uric acid and preparation method and application thereof | |
| CN101112498B (en) | Chinese traditional medicine having functions of promoting blood circulation, relaxing vein and strengthening muscles and bones and method for preparing the same | |
| CN108671094A (en) | It is a kind of to be used to treat pharmaceutical composition of gout and preparation method thereof | |
| CN103585515A (en) | Effervescing agent medicament for treating children alimentary anemia | |
| CN106266109A (en) | A kind of Chinese medicine composition treating urinary system calculus and preparation method thereof | |
| CN106267098A (en) | A kind of can effective Chinese medicine composition treating gout and preparation method thereof | |
| CN102579818A (en) | Traditional Tibetan medicine composition, preparation method thereof and application | |
| CN101987135A (en) | Medicine for treating tetanus and preparation method thereof | |
| CN103356798A (en) | Application of chronic-gastritis-treating traditional Chinese medicine in preparing medicine used for preventing gastric ulcer | |
| CN104623615A (en) | Medicine for treating asthma | |
| CN105106533B (en) | A kind of Chinese medicine composition for treating gestational period gall stone | |
| CN104367896B (en) | A kind of pharmaceutical composition for treating Qi deficiency blood stasis type apoplexy and preparation method thereof | |
| CN101028427B (en) | Chinese-medicinal decoction for treating hives | |
| CN108159150A (en) | A kind of Chinese medicine composition for treating rheumatic Bi syndrome and its preparation method and application | |
| CN109925399B (en) | Compound traditional Chinese medicine composition for treating coronary heart disease and angina pectoris and preparation method thereof | |
| CN100415279C (en) | A Chinese traditional medicinal preparation for treatment of urticaria | |
| CN104922397B (en) | A kind of promoting blood circulation and removing blood stasis, application of the Chinese medicine composition of hemostasis and pain-relieving | |
| CN104042935A (en) | Traditional Chinese medicine composition for treating cervical spondylopathy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20231219 Address after: No. 605, Building A, National Intellectual Property and Creative Industry Pilot Park, No. 60 Guoji Road, Jinshui District, Zhengzhou City, Henan Province, 450000 Patentee after: Zhengzhou Baoyu Medical Technology Co.,Ltd. Address before: 150040 Heping Road 24, Xiangfang District, Heilongjiang, Harbin Patentee before: HEILONGJIANG University OF CHINESE MEDICINE |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20231224 Address after: 1st to 9th floors of the office building on the south side of Red Star Macalline World Expo Home Furnishing Plaza, No.1 Gongnong Road, Qiaokou District, Wuhan City, Hubei Province, 430000 Patentee after: Wuhan Jing'e Tongpu Hospital Co.,Ltd. Address before: No. 605, Building A, National Intellectual Property and Creative Industry Pilot Park, No. 60 Guoji Road, Jinshui District, Zhengzhou City, Henan Province, 450000 Patentee before: Zhengzhou Baoyu Medical Technology Co.,Ltd. |
|
| TR01 | Transfer of patent right |